Genmab A/S (GMAB)

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members

Genmab: Epkinly Shines In Phase 3 DLBCL Trial

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?

Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Major Shareholder Announcement

Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4

Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High – What’s Next?

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Capital Increase in Genmab as a Result of Employee Warrant Exercise